We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App





New Rapid Test That Identifies Deteriorating COVID-19 Patients with Greater Accuracy than Existing Tests Presented at AACC 2021

By LabMedica International staff writers
Posted on 28 Sep 2021
Print article
Illustration
Illustration

A groundbreaking study on a new rapid test that identifies COVID-19 patients who will deteriorate with greater accuracy than existing tests was presented at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo.

A team of researchers from MeMed (Haifa, Israel) has developed the test that predicts COVID-19 outcomes with high accuracy. In 15 minutes, the test measures blood levels of TRAIL and IP-10, two proteins that the immune system produces in response to viral infections, and CRP, a general marker of infection severity. The test then uses these values to calculate a COVID-19 Severity score on a scale of 0-100, with 100 indicating the highest likelihood of severe outcome.

To develop this test, the researchers first used a rapid point-of-care instrument that MeMed previously built to measure TRAIL, IP-10, and CRP in a group of 518 COVID-19 patients, 113 of whom had a severe outcome. The researchers analyzed the data from this group with a machine learning algorithm in order to create the model that serves as the basis for the COVID-19 Severity score. Through statistical analysis, the researchers then determined that the COVID-19 Severity score has an area under the curve (AUC) of 0.86. This means that it outperforms other COVID-19 severity stratification tests in terms of accuracy, including the commonly used biomarker IL-6, which only has an AUC of 0.77.

“There are three elements that are novel about this test,” said Eran Eden, PhD, Co-founder & CEO of MeMed. “First, we’re using the body’s immune response to tell us what’s going on with the patient. Second, instead of using just one biomarker, we’re combining three complementary markers to get a more holistic picture. And third, we’re using a novel platform that is able to measure these specific proteins from blood within 15 minutes, making this test clinically applicable to the workflow in today’s emergency departments.”

Related Links:
MeMed

New
Gold Member
Veterinary Hematology Analyzer
Exigo H400
New
Gold Member
LEISHMANIA Test
LEISHMANIA ELISA
New
Automated Biochemistry Analyzer
AutoChem B861
New
Urine Drug Test
Instant-view Propoxyphene Urine Drug Test

Print article
ADLM

Channels

Immunology

view channel
Image: New research has revealed a novel biomarker for autoimmune diseases (Photo courtesy of Shutterstock)

Novel Analytical Method Tracks Progression of Autoimmune Diseases

Patients with autoimmune diseases often have lifelong contact with doctors and hospitals. The typical patient diagnosed is a woman in her fifties and the disease requires lifelong treatment.... Read more

Microbiology

view channel
Image: The unique barcoding system enables tracking of K. pneumoniae as it moves throughout the body (Photo courtesy of AdobeStock)

Unique Barcoding System Tracks Pneumonia-Causing Bacteria as They Infect Blood Stream

Bacteremia, also known as blood poisoning, occurs when bacteria manage to overcome the body's immune defenses. This condition can progress into sepsis, a serious illness that is responsible for over a... Read more

Pathology

view channel
Image: The squares are representative partial pictures from the cancer microscopy slides, that the AI system has automatically organized by their similarity (Photo courtesy of University of Jyväskylä)

New AI Tool Outperforms Previous Methods for Identifying Colorectal Cancer from Tissue Sample Analysis

Tissue analysis typically involves a pathologist reviewing scanned digital slides from a patient’s intestinal sample and marking specific areas, such as those where cancerous and related tissues are present.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.